Your institution may have access to this item. Find your institution then sign in to continue.
Title
FDA Approves Aphexda, in Combination With Filgrastim, to Mobilize Stem Cells for Transplant in Patients With Multiple Myeloma.
Abstract
The article focuses on the Food and Drug Administration (FDA) approval of motixafortide (Aphexda) in combination with filgrastim for mobilizing stem cells in multiple myeloma patients, based on the GENESIS study. Motixafortide showed efficacy in mobilizing hematopoietic stem cells for autologous stem cell transplantation (ASCT), proving particularly beneficial for older patients or those previously exposed to lenalidomide-containing induction regimens.